OrthoPediatrics

KIDS

Market cap $495M

WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 4, 2026 at 4:30 p.m. ET to discuss the results.

WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced an exclusive distribution agreement with OSSIO, Inc. (“OSSIO”) that brings U.S. children's hospitals nationwide a bio-integrative, metal-free fixation technology ideally suited for treatment of fractures and deformities in pediatric patients.

OrthoPediatrics Corp. (KIDS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

WARSAW, Ind., May 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Fred Hite, Chief Operating Officer, and Chief Financial Officer, is scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference, held in Miami Beach, FL.

First Financial Bancorp maintains a return on tangible common equity in the high teens, and we were able to buy the stock at an attractive valuation. We purchased shares of Guardant Health, as recent due diligence highlighted a stable competitive environment and underscored a number of positive catalysts for the company over the next several years. We exited our position in Dynatrace, Inc. to redeploy capital to other higher conviction names following the broad software de-rating.

OrthoPediatrics Corp. (KIDS) Q1 2026 Earnings Call Transcript

The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.39 per share a year ago.

WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2026.

WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with a new product launch, the TRAXIO Complete - Weight System, in collaboration with Synetik Group, Inc.